Company: DMAC
Filing Date: 2025-07-17
Form Type: 8-K
Source: 0001437749-25-022877
Chunk: 0

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-07-17
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01.      Regulation FD Disclosure.  

On July 17, 2025, DiaMedica Therapeutics Inc. (the "Company")issued a press release announcing positive interim results from Part 1a of the Phase 2 study of DM199 for the treatment of preeclampsia. A copy of such press release is being furnished as Exhibit 99.1 to this report.

Additionally, on July 17, 2025, the Company posted on its website a presentation summarizing the interim results from Part 1a of the Phase 2 study of DM199 for the treatment of preeclampsia, a copy of which is attached hereto as Exhibit 99.2.

The information, including Exhibits 99.1 and 99.2, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall otherwise be expressly set forth by specific reference in such filing.